Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer

Experimental and Molecular Pathology

Volumn 94, Issue 1, 2013, Pages 155-159

  Alsdorf, Winfried H ^a   Clauditz, Till S ^a   Hoenig, Tobias ^a   Quaas, Alexander ^a   Sirma, Hüseyin ^a   Koenig, Alexandra M ^a   Izbicki, Jakob ^a   Sauter, Guido ^a   Marx, Andreas H ^a   Grob, Tobias J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Heterogeneity; KRAS; Mutation analysis; Non small cell lung cancer

Indexed keywords

ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA EXTRACTION; DNA SCREENING; FALSE NEGATIVE RESULT; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE K RAS; SOMATIC MUTATION;

CARCINOMA, NON-SMALL-CELL LUNG; GENES, RAS; GENETIC VARIATION; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84870955954     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.09.016     Document Type: Article

References (40)

1. Badalian G., et al. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathology Oncology Research 2007, 13:99-104.
2. Balsara B.R., Testa J.R. Chromosomal imbalances in human lung cancer. Oncogene 2002, 21:6877-6883.
3. Bronte G., et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treatment Reviews 2010, 36(Suppl. 3):S21-S29.
4. Carey F.A., et al. Intratumoral heterogeneity of DNA content in lung cancer. Cancer 1990, 65:2266-2269.
5. Cortot A.B., et al. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010, 116:2682-2687.
6. Forbes S.A., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Research 2011, 39:D945-D950.
7. Forgacs E., et al. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathology Oncology Research 2001, 7:6-13.
8. Franklin W.A., et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. Journal of Molecular Diagnostics 2010, 12:43-50.
9. Gonzalez de Castro D., et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. British Journal of Cancer 2012, 107:345-351.
10. Graziano S.L., et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. Journal of Clinical Oncology 1999, 17:668-675.
11. Gysin S., et al. Therapeutic strategies for targeting ras proteins. Genes & Cancer 2011, 2:359-372.
12. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
13. Heideman D.A., et al. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. Journal of Molecular Diagnostics 2012, 14:247-255.
14. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. Journal of Clinical Oncology 2009, 27:4232-4235.
15. Husgafvel-Pursiainen K., et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. International Journal of Cancer 1993, 53:250-256.
16. Jemal A., et al. Cancer statistics, 2009. CA: A Cancer Journal for Clinicians 2009, 59:225-249.
17. Kalikaki A., et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. British Journal of Cancer 2008, 99:923-929.
18. Keohavong P., et al. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clinical Cancer Research 1996, 2:411-418.
19. Krypuy M., et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006, 6:295.
20. Langer C.J. Roles of EGFR and KRAS mutations in the treatment of patients with non-small-cell lung cancer. P T 2011, 36:263-279.
21. Li J., et al. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nature Medicine 2008, 14:579-584.
22. Lievre A., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research 2006, 66:3992-3995.
23. Marks J.L., et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. Journal of Thoracic Oncology 2008, 3:111-116.
24. Mattsson J.S., et al. Consistent mutation status within histologically heterogeneous lung cancer lesions. Histopathology 2012, 61:744-748.
25. Molina J.R., et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings 2008, 83:584-594.
26. Mulcahy H.E., et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clinical Cancer Research 1998, 4:271-275.
27. O'Byrne K.J., et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. The Lancet Oncology 2011, 12:795-805.
28. Ohshima S., et al. Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung. Virchows Archiv 1994, 424:129-134.
29. Riely G.J., et al. KRAS mutations in non-small cell lung cancer. Proceedings of the American Thoracic Society 2009, 6:201-205.
30. Roberts P.J., et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. Journal of Clinical Oncology 2010, 28:4769-4777.
31. Rodenhuis S., et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. The New England Journal of Medicine 1987, 317:929-935.
32. Santos E., et al. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 1984, 223:661-664.
33. Sauter G., et al. Tissue microarrays in drug discovery. Nature Reviews. Drug Discovery 2003, 2:962-972.
34. Schmid K., et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clinical Cancer Research 2009, 15:4554-4560.
35. Su Z., et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. Journal of Molecular Diagnostics 2011, 13:74-84.
36. Sun L., et al. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. Journal of Experimental & Clinical Cancer Research 2011, 30:30.
37. Van Cutsem E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine 2009, 360:1408-1417.
38. Westra W.H., et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993, 72:432-438.
39. Westra W.H., et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Research 1996, 56:2224-2228.
40. WHO World Health Organization Classification of Tumors 2004, 9-124. IARC Press, Lyon. W.D. Travis (Ed.).